Mustang Bio (MBIO) said Thursday that MB-108, an oncolytic virus currently undergoing phase 1 clinical trial for malignant glioma treatment, has been granted orphan drug designation by the US Food and Drug Administration.
The designation provides MB-108 seven years of market exclusivity in the US for the treatment.
Mustang also said it plans to seek orphan drug designation from the FDA for MB-101, an investigational CAR-T cell therapy for malignant gliomas.
The company said its novel strategy is to combine MB-108 oncolytic virus with MB-101 CAR-T cell therapy to optimize clinical results. It said both MB-101 and MB-108 are well tolerated in patients with recurrent glioblastoma, a type of brain tumor.
Shares of Mustang Bio were up more than 3% in recent trading.
Price: 0.25, Change: +0.01, Percent Change: +3.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。